CANF.A
Latest Trade
1.90USDChange
0.01(+0.53%)Volume
16,881Today's Range
-
1.9252 Week Range
-
2.95As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 1.89 |
|---|---|
Open | 1.85 |
Volume | 16,881 |
3M AVG Volume | 35.85 |
Today's High | 1.92 |
Today's Low | 1.83 |
52 Week High | 2.95 |
52 Week Low | 1.08 |
Shares Out (MIL) | 463.77 |
Market Cap (MIL) | 96.79 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Can-Fite Biopharma Says As Of September 30, 2020, Co Had Cash And Cash Equivalents Of $10.22 Million
FDA Clears Can-Fite To Commence Phase II COVID-19 Study
Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
Industry
Biotechnology & Drugs
Contact Info
10 Bareket Street, Kiryat Matalon,
P.O. Box 7537
4951778
Israel
+972.3.9241114
http://www.canfite.com/Executive Leadership
Ilan Cohen
Chairman of the Board
Pnina Fishman
Chief Executive Officer, Director
Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Golan Bitton
Director
Guy Regev
Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 37.78 |
Price To Book (MRQ) | 3.18 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -124.73 |
Return on Equity (TTM) | -100.14 |
* CAN FITE BIOPHARMA LTD FILES FOR OFFERING OF UP TO 96.7 MILLION ORDINARY SHARES BY THE SELLING SHAREHOLDERS - SEC FILING Source text (https://bit.ly/300uNl8) Further company coverage:
* CAN-FITE ANNOUNCES FINAL DATA ANALYSIS FROM PHASE II NASH STUDY: HIGHLY SIGNIFICANT AND SUSTAINED REDUCTION IN LIVER FAT VOLUME THROUGHOUT STUDY PERIOD
* CAN FITE BIOPHARMA LTD FILES PROSPECTUS SUPPLEMENT TO OFFER 117.1 MILLION ORDINARY SHARES REPRESENTED BY 3.9 MILLION ADSS - SEC FILING
* CAN FITE BIOPHARMA -PURCHASE & SALE OF 3.9 MILLION OF CO'S ADSS, AT PURCHASE PRICE OF $2.05/ADS, IN A REGISTERED DIRECT OFFERING Source text for Eikon: Further company coverage:
* FOLLOWING PRE-IND GUIDANCE FROM FDA CAN-FITE TO ADVANCE PICLIDENOSON INTO PHASE II COVID-19 TRIAL IN THE U.S.
* CAN-FITE CONCLUDES SUCCESSFUL MEETING WITH EUROPEAN MEDICINES AGENCY (EMA) REGARDING PHASE III TRIAL AND REGISTRATION PLAN FOR NAMODENOSON IN THE TREATMENT OF LIVER CANCER
* CAN-FITE REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS & PROVIDES CLINICAL UPDATE
* CAN-FITE RECEIVES NOTICE OF ALLOWANCE FOR NAMODENOSON PATENT IN THE TREATMENT OF NASH & NAFLD FROM U.S. PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* CAN-FITE REPORTS ADDITIONAL FINDINGS FROM SUCCESSFUL PHASE II NASH STUDY: 25 MG DOSE OF NAMODENOSON SIGNIFICANTLY REDUCED LIVER FAT AND FIBROSIS
* CAN-FITE ANNOUNCES PRE-IND SUBMISSION TO U.S. FDA FOR PICLIDENOSON IN THE TREATMENT OF COVID-19 INFECTED PATIENTS WITH MODERATE-TO-SEVERE SYMPTOMS
* CAN FITE RECEIVED APPROVAL FOR COVID-19 CLINICAL TRIAL IN ISRAEL, PATIENT ENROLLMENT AND DOSING TO COMMENCE IMMEDIATELY Source text for Eikon: Further company coverage:
* CAN-FITE REPORTS POSITIVE TOP LINE RESULTS FROM ITS PHASE II NASH STUDY WITH NAMODENOSON
* CAN-FITE IMPLEMENTS INTERIM ANALYSIS FOR ITS PHASE III PSORIASIS TRIAL WITH DATA EXPECTED Q4 2020
* CAN-FITE REPORTS 2019 FINANCIAL RESULTS & PROVIDES CLINICAL DEVELOPMENT UPDATE
* CAN FITE BIOPHARMA LTD - PICLIDENOSON SUBMITTED FOR COMPASSIONATE USE TREATMENT FOR CORONAVIRUS PATIENTS IN ISRAEL Source text for Eikon: Further company coverage:
* CAN FITE BIOPHARMA LTD - LOOKS TO PARTNER ON CO-DEVELOPMENT OF PICLIDENOSON FOR CORONAVIRUS TREATMENT Source text for Eikon: Further company coverage:
* CAN FITE BIOPHARMA LTD - ENROLLED 7 PATIENTS FOR COMPASSIONATE USE PROGRAM FOR NAMODENOSON IN TREATMENT OF HEPATOCELLULAR CANCER
* CAN-FITE TO EXPLORE THE ANTI-CORONAVIRUS EFFECTS OF PICLIDENOSON IN COLLABORATION WITH LEWIS KATZ SCHOOL OF MEDICINE AT TEMPLE UNIVERSITY Source text for Eikon: Further company coverage:
* CAN-FITE UPDATES ON CLINICAL MILESTONE FOR ITS PHASE III RHEUMATOID ARTHRITIS STUDY WITH PICLIDENOSON; DRUGS COMBATING RHEUMATOID ARTHRITIS ARE CURRENTLY INTRODUCED FOR THE TREATMENT OF THE CORONAVIRUS
* CAN FITE BIOPHARMA - FILING DRUG SAFETY UPDATE REPORT SHOWING POSITIVE SAFETY RESULTS FROM PHASE II & PHASE III STUDIES OF NAMODENOSON & PICLIDENOSON Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.